A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments
Kopetz, S. Morris, V. K. O'Neil, B. Bridgewater, J. A. Graham, J. Parkes, E. E. Saunders, Mark P Asken, E. Goodwin, L. Phillips, C.
Kopetz, S.
Morris, V. K.
O'Neil, B.
Bridgewater, J. A.
Graham, J.
Parkes, E. E.
Saunders, Mark P
Asken, E.
Goodwin, L.
Phillips, C.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Kopetz S, Morris VK, O'Neil B, Bridgewater JA, Graham J, Parkes EE, et al. A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304904.